Is Huntington's disease a tauopathy?

Brain

Volumn 139, Issue 4, 2016, Pages 1014-1025

  Gratuze, Maud ^a,b   Cisbani, Giulia ^a,b   Cicchetti, Francesca ^a,b   Planel, Emmanuel ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Huntington's disease; tau

Indexed keywords

TAU PROTEIN;

ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; ARTICLE; CALCIUM HOMEOSTASIS; CLINICAL FEATURE; CONFORMATIONAL TRANSITION; HAPLOTYPE; HUMAN; HUNTINGTON CHOREA; IMMUNOREACTIVITY; MICROTUBULE ASSEMBLY; MOTOR PERFORMANCE; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NERVE FIBER TRANSPORT; NEUROFIBRILLARY TANGLE; NONHUMAN; OLIGOMERIZATION; PAIRED HELICAL FILAMENT; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TAUOPATHY; ANIMAL; BRAIN; CLINICAL TRIAL (TOPIC); GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROCEDURES;

ANIMALS; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; HUNTINGTON DISEASE; PHOSPHORYLATION; TAU PROTEINS; TAUOPATHIES;

EID: 84964502075     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww021     Document Type: Article

References (78)

1. Alonso AC, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA 2001; 98: 6923-8.
2. Ando K, Leroy K, Heraud C, Yilmaz Z, Authelet M, Suain V, et al. Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. Am J Pathol 2011; 178: 803-16.
3. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 2003; 86: 582-90.
4. Andreasen N, Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg 2005; 107: 165-73.
5. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992; 42(3 Pt 1): 631-9.
6. Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev 2004; 84: 361-84.
7. Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Wiche G, et al. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res 1989; 477: 90-9.
8. Blum D, Herrera F, Francelle L, Mendes T, Basquin M, Obriot H, et al. Mutant huntingtin alters Tau phosphorylation and subcellular distribution. Hum Mol Genet 2015; 24: 76-85.
9. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
10. Bretteville A, Planel E. Tau aggregates: toxic, inert, or protective species? J Alzheimers Dis 2008; 14: 431-6.
11. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000; 33: 95-130.
12. Caffrey TM, Wade-Martins R. The role of MAPT sequence variation in mechanisms of disease susceptibility. Biochem Soc Trans 2012; 40: 687-92.
13. Caparros-Lefebvre D, Kerdraon O, Devos D, Dhaenens CM, Blum D, Maurage CA, et al. Association of corticobasal degeneration and Huntington's disease: can Tau aggregates protect Huntingtin toxicity? Mov Disord 2009; 24: 1089-90.
14. Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 2014; 34: 4260-72.
15. Cicchetti F, Lacroix S, Cisbani G, Vallieres N, Saint-Pierre M, St-Amour I, et al. Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol 2014; 76: 31-42.
16. Cisbani G, Cicchetti F. An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity. Cell Death Dis 2012; 3: e382
17. Drouin-Ouellet J, Sawiak SJ, Cisbani G, Lagace M, Kuan WL, Saint-Pierre M, et al. Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology. Ann Neurol 2015; 78: 160-77.
18. Constantinescu R, Romer M, Zetterberg H, Rosengren L, Kieburtz K. Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease. Parkinsonism Relat Disord 2011; 17: 714-15.
19. Davis MY, Keene CD, Jayadev S, Bird T. The co-occurrence of Alzheimer's disease and Huntington's disease: a neuropathological study of 15 elderly Huntington's disease subjects. J Huntingtons Dis 2014; 3: 209-17.
20. de Silva R, Lashley T, Strand C, Shiarli AM, Shi J, Tian J, et al. An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R-and 4R-specific tau monoclonal antibodies. Acta Neuropathol 2006; 111: 329-40.
21. Deckel AW, Elder R, Fuhrer G. Biphasic developmental changes in Ca2 + /calmodulin-dependent proteins in R6/2 Huntington's disease mice. Neuroreport 2002; 13: 707-11.
22. Delacourte A, Sergeant N, Wattez A, Gauvreau D, Robitaille Y. Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation. Ann Neurol 1998; 43: 193-204.
23. Duyckaerts C, Bennecib M, Grignon Y, Uchihara T, He Y, Piette F, et al. Modeling the relation between neurofibrillary tangles and intellectual status. Neurobiol Aging 1997; 18: 267-73.
24. Fernandez-Nogales M, Cabrera JR, Santos-Galindo M, Hoozemans JJ, Ferrer I, Rozemuller AJ, et al. Huntington's disease is a four-repeat tauopathy with tau nuclear rods. Nat Med 2014; 20: 881-5.
25. Fernandez-Nogales M, Hernandez F, Miguez A, Alberch J, Gines S, Perez-Navarro E, et al. Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease. Hum Mol Genet 2015; 24: 5040-52.
26. Gao QS, Memmott J, Lafyatis R, Stamm S, Screaton G, Andreadis A. Complex regulation of tau exon 10, whose missplicing causes frontotemporal dementia. J Neurochem 2000; 74: 490-500.
27. Gerson JE, Kayed R. Formation and propagation of tau oligomeric seeds. Front Neurol 2013; 4: 93.
28. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003; 60: 1495-500.
29. Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Vandermeeren M, et al. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J 1994; 301(Pt 3): 871-7.
30. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997; 41: 17-24.
31. Goto S, Hirano A, Rojas-Corona RR. An immunohistochemical investigation of the human neostriatum in Huntington's disease. Ann Neurol 1989; 25: 298-304.
32. Gratuze M, Noel A, Julien C, Cisbani G, Milot-Rousseau P, Morin F, et al. Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease. Hum Mol Genet 2015; 24: 86-99.
33. Group THsDCR. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-83.
34. Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in ageing and mild cognitive impairment. Arch Neurol 2003; 60: 729-36.
35. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 1999; 19: 2522-34.
36. Hedreen JC, Folstein SE. Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol 1995; 54: 105-20.
37. Hodges A, Strand Ad, Aragaki AK, Kuhn A, Sengstag T, Hughes G, et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 2006; 15: 965-77.
38. Hoffner G, Kahlem P, Djian P. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. J Cell Sci 2002; 115(Pt 5): 941-8.
39. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702-5.
40. Jellinger KA. Alzheimer-type lesions in Huntington's disease. J Neural Transm 1998; 105: 787-99.
41. Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res 1997; 48: 128-32.
42. Jones EL, Margallo-Lana M, Prasher VP, Ballard CG. The extended tau haplotype and the age of onset of dementia in Down syndrome. Dement Geriatr Cogn Disord 2008; 26: 199-202.
43. Kimura T, Ono T, Takamatsu J, Yamamoto H, Ikegami K, Kondo A, et al. Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments. Dementia 1996; 7: 177-81.
44. Kovacs GG. Invited review: Neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol 2015; 41: 3-23.
45. Li SH, Li XJ. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 2004; 20: 146-54.
46. Lievens JC, Woodman B, Mahal A, Bates GP. Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice. Mol Cell Neurosci 2002; 20: 638-48.
47. Lim D, Fedrizzi L, Tartari M, Zuccato C, Cattaneo E, Brini M, et al. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J Biol Chem 2008; 283: 5780-9.
48. Lim NK, Hung LW, Pang TY, McLean CA, Liddell JR, Hilton JB, et al. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain. Hum Mol Genet 2014; 23: 4051-63.
49. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 2005; 22: 1942-50.
50. Luo S, Vacher C, Davies JE, Rubinsztein DC. Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J Cell Biol 2005; 169: 647-56.
51. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 2000; 9: 1259-71.
52. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the Huntington's disease gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
53. Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, et al. Tau protein kinases: involvement in Alzheimer's disease. Ageing Res Rev 2013; 12: 289-309.
54. Maurage CA, Sergeant N, Ruchoux MM, Hauw JJ, Delacourte A. Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology. Acta Neuropathol (Berl) 2003; 105: 89-97.
55. McIntosh GC, Jameson Hd, Markesbery WR. Huntington disease associated with Alzheimer disease. Ann Neurol 1978; 3: 545-8.
56. Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. PLoS One 2012; 7: e49838
57. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 2003; 465: 11-26.
58. Mitchell IJ, Cooper AJ, Griffiths MR. The selective vulnerability of striatopallidal neurons. Prog Neurobiol 1999; 59: 691-719.
59. Moss RJ, Mastri AR, Schut LJ. The coexistence and differentiation of late onset Huntington's disease and Alzheimer's disease. A case report and review of the literature. J Am Geriatr Soc 1988; 36: 237-41.
60. Myers RH, Sax Ds, Schoenfeld M, Bird ED, Wolf PA, Vonsattel JP, et al. Late onset of Huntington's disease. J Neurol Neurosurg Psychiatry 1985; 48: 530-4.
61. Rajput PS, Kharmate G, Norman M, Liu SH, Sastry BR, Brunicardi CF, et al. Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic mice. PLoS One 2011; 6: e24467
62. Revesz T, Holton JL. Anatamopathological spectrum of tauopathies. Mov Disord 2003; 18 (Suppl 6): S13-20.
63. Reyes MG, Gibbons S. Dementia of the Alzheimer's type and Huntington's disease. Neurology 1985; 35: 273-7.
64. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10: 83-98.
65. Sato S, Tatebayashi Y, Akagi T, Chui DH, Murayama M, Miyasaka T, et al. Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells. J. Biol Chem 2002; 277: 42060-5.
66. Sergeant N, Wattez A, Delacourte A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms. J Neurochem 1999; 72: 1243-9.
67. Singhrao SK, Thomas P, Wood JD, MacMillan JC, Neal JW, Harper PS, et al. Huntingtin protein colocalizes with lesions of neurodegenerative diseases: An investigation in Huntington's, Alzheimer's, and Pick's diseases. Exp Neurol 1998; 150: 213-22.
68. Trojanowski JQ, Lee VM. Paired helical filament tau in Alzheimer's disease. The kinase connection. Am J Pathol 1994; 144: 449-53.
69. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr.. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-77.
70. Vuono R, Winder-Rhodes S, de Silva R, Cisbani G, Drouin-Ouellet J, Spillantini MG, et al. The role of tau in the pathological process and clinical expression of Huntington's disease. Brain 2015; 138(Pt 7): 1907-18.
71. Wang Y, Wang J, Gao L, Lafyatis R, Stamm S, Andreadis A. Tau exons 2 and 10, which are misregulated in neurodegenerative diseases, are partly regulated by silencers which bind a SRp30c.SRp55 complex that either recruits or antagonizes htra2beta1. J Biol Chem 2005; 280: 14230-9.
72. Wilcock GK, Esiri MM. Plaques, tangles and dementia. A quantitative study. J Neurol Sci 1982; 56: 343-56.
73. Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JR, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J Clin Investig 2015; 125: 1979-86.
74. Xifro X, Giralt A, Saavedra A, Garcia-Martinez JM, Diaz-Hernandez M, Lucas JJ, et al. Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity. Neurobiol Dis 2009; 36: 461-9.
75. Yin X, Jin N, Gu J, Shi J, Zhou J, Gong CX, et al. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted Tau exon 10 inclusion. J Biol Chem 2012; 287: 30497-506.
76. Young AB. Huntingtin in health and disease. J Clin Invest 2003; 111: 299-302.
77. Yu Q, Guo J, Zhou J. A minimal length between tau exon 10 and 11 is required for correct splicing of exon 10. J Neurochem 2004; 90: 164-72.
78. Zheng Z, Diamond MI. Huntington disease and the huntingtin protein. Prog Mol Biol Transl Sci 2012; 107: 189-214.